Is Biogen Inc (BIIB) overvalued? · P/E 21, rev $9.89B
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
This page asks whether Biogen Inc (BIIB) looks expensive on cached numbers — not a short thesis.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BIIB 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BIIB stock page for the full model, not this heading.
Not investment advice.